SCHEMBL3377091

SCHEMBL3377091

CC(O)Cc1ccccc1C(N)=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 2/20 0.47
HTT P42858 1/20 0.45
ALDH1A1 P00352 3/20 0.44
MAPT P10636 2/20 0.44
TSHR P16473 2/20 0.44
KDM4E B2RXH2 2/20 0.44
HPGD P15428 1/20 0.44
HSD17B10 Q99714 1/20 0.44
METAP2 P50579 1/20 0.41
KMT2A Q03164 3/20 0.40
BCAT2 O15382 1/20 0.40
KEAP1 Q14145 1/20 0.40
NFE2L2 Q16236 1/20 0.40
MEN1 O00255 2/20 0.39
PARP1 P09874 1/20 0.38
NR1I2 O75469 1/20 0.38
LMNA P02545 1/20 0.38
CHRM2 P08172 1/20 0.38
CYP3A4 P08684 1/20 0.38
ADRA2A P08913 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8507009 1.00 IRAK4 (0.47) IRAK4HTTALDH1A1MAPTTSHR
SCHEMBL8508451 1.00 IRAK4 (0.47) IRAK4HTTALDH1A1MAPTTSHR
SCHEMBL1002816 0.87 HTT (0.50) IRAK4HTTALDH1A1MAPTTSHR
SCHEMBL17374631 0.85 IRAK4 (0.47) IRAK4HTTALDH1A1MAPTTSHR
SCHEMBL28845213 0.85 KDM4E (0.47) IRAK4HTTALDH1A1MAPTTSHR
SCHEMBL5575146 0.85 TSHR (0.40) ALDH1A1MAPTTSHRHPGDKMT2A
SCHEMBL29136235 0.84 IRAK4 (0.40) IRAK4HTTALDH1A1MAPTTSHR
SCHEMBL5935461 0.84 IRAK4 (0.40) IRAK4HTTALDH1A1MAPTTSHR
SCHEMBL30776574 0.84 IRAK4 (0.40) IRAK4HTTALDH1A1MAPTTSHR
SCHEMBL19143527 0.82 KDM4E (0.49) IRAK4HTTALDH1A1MAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117776953-A Preparation method of N, N-di (beta-hydroxypropyl) benzamide 南京红宝丽醇胺化学有限公司 2024-03-29 CN claimed
EP-0934264-A1 PYRROLIDINYL AND PYRROLINYL ETHYLAMINE COMPOUNDS AS KAPPA AGONISTS PFIZER INC. (US) 1999-08-11 EP claimed
WO-1998012177-A1 PYRROLIDINYL AND PYRROLINYL ETHYLAMINE COMPOUNDS AS KAPPA AGONISTS PFIZER INC. (JP) 1998-03-26 WO claimed
EP-4377318-A1 PYRROLO [2, 3-B] PYRAZINE-BASED BIFUNCTIONAL COMPOUNDS AS HPK1 DEGRADERS AND THE USE THEREOF BeiGene, Ltd. (KY) 2024-06-05 EP disclosed
US-11964953-B2 Substituted aminothiazoles as DGKzeta inhibitors for immune activation BAYER AKTIENGESELLSCHAFT (DE) 2024-04-23 US disclosed
CN-117801589-A Matting agent for powder coating and application thereof, matting powder coating and application thereof 安徽省华安进出口有限公司 2024-04-02 CN disclosed
CN-117776953-A Preparation method of N, N-di (beta-hydroxypropyl) benzamide 南京红宝丽醇胺化学有限公司 2024-03-29 CN disclosed
CN-117776953-A Preparation method of N, N-di (beta-hydroxypropyl) benzamide 南京红宝丽醇胺化学有限公司 2024-03-29 CN disclosed
CN-117776953-A Preparation method of N, N-di (beta-hydroxypropyl) benzamide 南京红宝丽醇胺化学有限公司 2024-03-29 CN disclosed
CN-116410105-A Preparation method of difunctional alkylbenzene hydroxyalkylamide 南京红宝丽醇胺化学有限公司 2023-07-11 CN disclosed
CN-115093732-B Low-functionality curing agent blend and high-gloss powder coating 安徽省华安进出口有限公司 2023-05-23 CN disclosed
WO-2019238067-A1 PYRROLO [2, 3-B] PYRIDINES OR PYRROLO [2, 3-B] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF BEIGENE, LTD. (KY) 2019-12-19 WO disclosed
US-9447033-B2 Potassium channel blockers JAPAN TOBACCO INC. (JP) 2016-09-20 US disclosed
US-20150259282-A1 Potassium Channel Blockers XENTION LIMITED (GB) 2015-09-17 US disclosed
US-9073834-B2 Potassium channel blockers XENTION LIMITED (GB) 2015-07-07 US disclosed
US-20140221337-A1 Potassium Channel Blockers XENTION LIMITED (GB) 2014-08-07 US disclosed
US-8673901-B2 Potassium channel blockers XENTION LIMITED (GB) 2014-03-18 US disclosed
US-20100087428-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed
EP-0934264-A1 PYRROLIDINYL AND PYRROLINYL ETHYLAMINE COMPOUNDS AS KAPPA AGONISTS PFIZER INC. (US) 1999-08-11 EP disclosed
WO-1998012177-A1 PYRROLIDINYL AND PYRROLINYL ETHYLAMINE COMPOUNDS AS KAPPA AGONISTS PFIZER INC. (JP) 1998-03-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221337-A1 Potassium Channel Blockers KCNJ2, KCNH2, KCNB1 IRAK4 2907/4885HTT 2305/4885ALDH1A1 1360/4885
US-20100087428-A1 Novel Potassium Channel Blockers HCN4, SCN2B, KCNH2 IRAK4 2942/4885HTT 2035/4885ALDH1A1 3795/4885
US-11964953-B2 Substituted aminothiazoles as DGKzeta inhibitors for immune activation DGKZ, DGKA, DGKG IRAK4 381/4885HTT 3914/4885ALDH1A1 3985/4885
US-20150259282-A1 Potassium Channel Blockers KCNJ2, KCNH2, KCNB1 IRAK4 2907/4885HTT 2305/4885ALDH1A1 1360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.